The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of clinical pharmacology

• Publication date

  2007-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270006295060PMID 17192505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity

  2005cited by this paper
• Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38

  2004cited by this paper
• Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38

  2004cited by this paper
• Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity

  2004cited by this paper
• Irinotecan pharmacogenetics: is it time to intervene?

  2004cited by this paper
• UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer

  2004cited by this paper
• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  2004cited by this paper
• UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

  2004cited by this paper
• Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

  2003cited by this paper
• Irinotecan pathway genotype analysis to predict pharmacokinetics.

  2003cited by this paper
• Polymorphisms of UDP-Glucuronosyltransferase and Pharmacokinetics of Irinotecan

  2002cited by this paper
• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

  2002influential reference
• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  2001influential reference
• Genetic lesions of bilirubin uridine‐diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler‐Najjar and Gilbert syndromes: Correlation of genotype to phenotype

  2000cited by this paper
• Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

  1998cited by this paper
• UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.

  1998cited by this paper
• Efficacy and toxicity of irinotecan in patients with colorectal cancer.

  1998cited by this paper
• Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.

  1997cited by this paper
• Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome

  1996cited by this paper
• A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini.

  1992cited by this paper

• Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review

  2025cites this paper
• Beyond cytotoxic potency: disposition features required to design ADC payload

  2024influential citation
• Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the Spectrofluorimetric Method

  2024cites this paper
• Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi® Long-Read and Illumina Short-Read Sequencing

  2023cites this paper
• Preclinical safety, toxicokinetics and metabolism of BIIB131, a novel prothrombolytic agent for acute stroke.

  2023cites this paper
• Prediction of Drug–Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation

  2022cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors

  2022cites this paper
• Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model

  2022cites this paper
• In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions.

  2021cites this paper
• Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

  2021cites this paper
• Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen

  2021cites this paper
• Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients

  2021cites this paper
• Combination of dabrafenib with irinotecan might trigger off a higher frequency of adverse events by pharmacokinetic interaction

  2021cites this paper
• The pharmacokinetic interaction between irinotecan and sunitinib

  2019cites this paper
• Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors

  2019cites this paper
• Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.

  2019cites this paper
• Principles of Dose, Schedule, and Combination Therapy

  2019cites this paper
• Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity.

  2018cites this paper
• Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma

  2018cites this paper
• Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens

  2018cites this paper
• Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer

  2017cites this paper
• Germline genetic variants with implications for disease risk and therapeutic outcomes.

  2017cites this paper
• Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer.

  2017cites this paper
• Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients

  2017cites this paper
• The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance

  2016cites this paper
• ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia

  2016cites this paper
• UGT1A1 genotype‐dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation

  2016cites this paper
• Fasting protects against the side effects of irinotecan treatment but does not affect anti‐tumour activity in mice

  2016cites this paper
• Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review

  2016cites this paper
• Personalized Medicine in Gastroenterology

  2016cites this paper
• Application of molecular profiling in clinical trials for advanced metastatic cancers.

  2015cites this paper
• Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage

  2015cites this paper
• Inhibition of SN-38 glucuronidation by gefitinib and its metabolite

  2015cites this paper
• Pharmacogénétique des analogues nucléosidiques : Cytidine déaminase et issue clinique

  2015cites this paper
• Novel pharmacogenomic markers of irinotecan-induced severe toxicity in metastatic colorectal cancer patients

  2015cites this paper
• CYP 2C19 and UDP-glucuronosyltransferases not only for drugs but also for endobiotics

  2014cites this paper
• Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

  2014cites this paper
• Extended mathematical model for “in vivo” quantification of the interaction betweeen atazanavir and bilirubin

  2014cites this paper
• Pharmacogenetic biomarkers for predicting drug response

  2014cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients

  2013cites this paper
• PRECLINICAL AND CLINICAL DEVELOPMENT OF THE LIPOPHILIC CAMPTOTHECIN ANALOGUE AR-67

  2013cites this paper
• Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity

  2013cites this paper
• 6. Hydrolytic Enzymes

  2012cites this paper
• UGT1A1*28 and *6 polymorphisms and nilotinib-induced unconjugated hyperbilirubinemia in a Japanese patient with chronic myelogenous leukemia

  2012cites this paper
• 13. Reaction Phenotyping

  2012cites this paper
• Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.

  2011cites this paper
• Metabolism of the c-Fos/Activator Protein-1 Inhibitor T-5224 by Multiple Human UDP-Glucuronosyltransferase Isoforms

  2011cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Pharmacogenetic Risk for Adverse Reactions to Irinotecan in the Major Ethnic Populations of Singapore

  2011cites this paper
• Regulatory Considerations in Metabolism‐ and Transporter‐Based Drug Interactions

  2011cites this paper
• When do you need a validated assay?

  2011cites this paper
• Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.

  2011cites this paper
• Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study

  2010cites this paper
• Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system

  2010cites this paper
• Drug interactions evaluation: an integrated part of risk assessment of therapeutics.

  2010influential citation
• The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

  2010cites this paper
• Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

  2010cites this paper
• Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors

  2009cites this paper
• Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

  2009cites this paper
• Irinotecan in Cancer Patients with End-Stage Renal Failure

  2009cites this paper
• Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

  2009cites this paper
• Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

  2009cites this paper
• UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?

  2009cites this paper
• UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients

  2009cites this paper
• Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

  2009cites this paper
• Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

  2009cites this paper
• HUMAN CARBOXYLESTERASE 2 SPLICE VARIANTS: EXPRESSION, ACTIVITY, AND ROLE IN THE METABOLISM OF IRINOTECAN AND CAPECITABINE

  2009cites this paper
• Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors

  2008cites this paper
• Pharmacogenetics in Cancer Management: Scenario for Tailored Therapy

  2008cites this paper
• [General concepts and study methods in pharmacogenetics].

  2008cites this paper
• Medical education: a key partner in realizing personalized medicine in gastroenterology.

  2008cites this paper
• Pharmacogenomics of tamoxifen and irinotecan therapies.

  2008cites this paper
• Clinical and pharmacogenetic factors associated with irinotecan toxicity.

  2008cites this paper
• Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

  2008cites this paper
• Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer

  2008cites this paper
• Systemic therapy for metastatic colorectal cancer

  2008cites this paper
• Irinotecan pharmacogenetics: An overview for the community oncologist

  2008cites this paper
• Conceptos generales y métodos de estudio en farmacogenética

  2008cites this paper
• Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics

  2008cites this paper
• Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity

  2007cites this paper
• AN ADAPTIVE BAYESIAN APPROACH TO JOINTLY MODELING RESPONSE AND TOXICITY IN PHASE I DOSE-FINDING TRIALS

  2007cites this paper
• Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

  2007cites this paper
• Obesity in Dose Calculation: A Mouse or

  2007cites this paper
• Pharmacogenetics and stomach cancer: an update.

  2007cites this paper
• Obesity in dose calculation: a mouse or an elephant?

  2007cites this paper
• Clinics in Oncology

  year unknowncites this paper